(2R,4R)-1-(tert-butoxycarbonyl)-2-methylpiperidine-4-carboxylic acid | 1250959-07-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (2R,4R)-1-(tert-butoxycarbonyl)-2-methylpiperidine-4-carboxylic acid
• 英文别名: (2R,4R)-1-(tert-Butoxycarbonyl)-2-methylpiperidine-4-carboxylic acid；(2R,4R)-2-methyl-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid
• CAS: 1250959-07-9
• 化学式: C₁₂H₂₁NO₄
• mdl: MFCD28139503
• 分子量: 243.303
• InChiKey: JYCRXMSJGZWACP-RKDXNWHRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2R,4R)-1-(tert-butoxycarbonyl)-2-methylpiperidine-4-carboxylic acid 在 4-二甲氨基吡啶 、 正丁基锂 、 二异丙胺 作用下， 以 四氢呋喃 、 叔丁醇 为溶剂， 反应 6.0h， 生成 di-tert-butyl (2R,4R)-4-((6-chloro-5-fluoro-4-methylpyridin-2-yl)methyl)-2-methylpiperidine-1,4-dicarboxylate
  参考文献：
  名称：

  [EN] NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS
  [FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES UTILES EN TANT QU'INHIBITEURS SÉLECTIFS D'AURORA A

  摘要：

  提供的是式（I）的化合物，或其药学上可接受的盐，可用于抑制Aurora A的活性并治疗由Aurora A介导的癌症。

  公开号：

  WO2021147974A1
• 作为产物：
  描述：

  1-(tert-butyl) 4-methyl (2R,4R)-2-methylpiperidine-1,4-dicarboxylate 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 以14.85 g的产率得到(2R,4R)-1-(tert-butoxycarbonyl)-2-methylpiperidine-4-carboxylic acid
  参考文献：
  名称：

  (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use

  摘要：

  本申请涉及新型取代的(氮杂)吡啶吡唑吡嘧啶酮和吲唑吡嘧啶酮，以及它们的制备方法，这些化合物可单独或组合使用于治疗和/或预防疾病的方法中，特别是用于治疗和/或预防患有或不患有基础遗传或获得性出血性疾病的患者的急性和复发性出血，其中出血与来自月经过多、产后出血、出血性休克、创伤、手术、移植、中风、肝病、遗传性血管性水肿、鼻血和血液性关节积血后的滑膜炎和软骨损伤等疾病或医疗干预有关。

  公开号：

  US20150126449A1

文献信息

• [EN] (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS<br/>[FR] (AZA)PYRIDOPYRAZOLOPYRIMIDINONES ET INDAZOLOPYRIMIDINONES UTILISÉES COMME INHIBITEURS DE LA FIBRINOLYSE
  申请人：BAYER PHARMA AG

  公开号：WO2015067549A1

  公开（公告）日：2015-05-14

  The present application relates to novel substituted (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired bleeding disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of menorrhagia, postpartum hemorrhage, hemorrhagic shock, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

  本申请涉及新型取代的(氮杂)吡啶吡唑吡嘧啶酮和吲唑吡嘧啶酮，以及它们的制备方法，这些化合物可单独或组合使用于治疗和/或预防疾病的方法中，特别是用于治疗和/或预防患有或不患有基础遗传或获得性出血性疾病的患者的急性和复发性出血，其中出血与来自以下组中选择的疾病或医疗干预相关，该组包括月经过多、产后出血、出血性休克、创伤、手术、移植、中风、肝病、遗传性血管性水肿、鼻血、以及血液积聚后的滑膜炎和软骨损伤。
• Piperidinylpyrazolopyrimidinones and their use
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US10118930B2

  公开（公告）日：2018-11-06

  The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

  本申请涉及新型取代的哌啶基吡唑嘧啶酮、其制备工艺、化合物在治疗和/或预防疾病的方法中的单独使用或组合使用，特别是用于治疗和/或预防有或没有潜在遗传性或获得性止血障碍的患者的急性和复发性出血、其中，出血与疾病或医疗干预有关，这些疾病或医疗干预选自月经大量出血、产后出血、失血性休克、出血性膀胱炎、胃肠道出血、创伤、手术、移植、中风、肝脏疾病、遗传性血管性水肿、鼻出血以及血汗管病后的滑膜炎和软骨损伤组成的组。
• Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
  申请人：Janssen Sciences Ireland Unlimited Company

  公开号：US11053235B2

  公开（公告）日：2021-07-06

  The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

  该申请描述了可用于治疗或预防 HBV 感染或 HBV 引起的疾病，特别是 HBV 慢性感染或 HBV 慢性感染引起的疾病的二氢嘧啶衍生物，以及其在制药或医疗方面的应用。
• Heterocyclic compounds useful as aurora a selective inhibitors
  申请人：Jacobio Pharmaceuticals Co., Ltd.

  公开号：US11384066B1

  公开（公告）日：2022-07-12

  Provided are compounds of formula (I), or pharmaceutically acceptable salts thereof, which can be used for inhibiting the activity of Aurora A and treating cancer mediated by Aurora A.

  所提供的式 (I) 化合物或其药学上可接受的盐类可用于抑制 Aurora A 的活性和治疗由 Aurora A 介导的癌症。
• Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors
  作者：Jesus M. Ontoria、Laura Llauger Bufi、Caterina Torrisi、Alberto Bresciani、Claudia Giomini、Michael Rowley、Sergio Serafini、Hu Bin、Wu Hao、Christian Steinkühler、Philip Jones

  DOI：10.1016/j.bmcl.2011.07.031

  日期：2011.9

  The Hedgehog (Hh-) signalling pathway is a key developmental pathway and there is a growing body of evidence showing that this pathway is aberrantly reactivated in a number of human tumors. Novel agents capable of inhibiting this pathway are sought, and an entirely novel series of smoothened (Smo) antagonists capable of inhibiting the pathway have been identified through uHTS screening. Extensive exploration of the scaffold identified the key functionalities necessary for potency, enabling potent nanomolar Smo antagonists like 91 and 94 to be developed. Optimization resulted in the most advanced compounds displaying low serum shift, clean off-targets profile, and moderate clearance in both rats and dogs. These compounds are valuable tools with which to probe the biology of the Hh-pathway. (C) 2011 Elsevier Ltd. All rights reserved.